<font> A VERY SPECIAL GLOBAL EQUITY REPORT: </font>
<font>
</font> <font> $BONU Bests Pfizer and Purell(R) with Amazing New Antibacterial Product 'Ygiene' </font>
<font>
</font> <font> Bioneutral Group ( $BONU ) just introduced its ‘Ygiene(TM)’ antibacterial, which is very similar to Purell(R) Hand Sanitizer except it also kills Anthrax! Although Purell claims to eradicate <font> 99.99% </font> of most common germs, the product fails to kill Anthrax; on the other hand, Ygiene(TM) kills <font> 99.97% </font> of greenhouse gases , formaldehyde, black mold and Anthrax.
</font> <font> <font> Ygiene(TM) is like a Purell(R) that also kills Anthrax, and that’s why there is a huge opportunity for $BONU! </font> The market for Purell(R) has exploded and with America's fear-factor at an all-time high its only a matter of time before $PFE and $JNJ begin paying attention to $BONU 's Ygiene(TM) Product. </font>
<font>
A member of the New York City ’s Taskforce on Bioterrorism , Phillip Tierno, had this to say about Ygiene:
</font> <font> “There is nothing better. (Virtually nothing compares with it). </font>
<font> There is nothing that works faster. (Kills in seconds). </font>
<font> There is nothing that has a more complete kill. (Kills 100% of organisms). </font>
<font> There is nothing wider in spectrum. (Kills any and all microbes). </font>
<font> And it is an environmentally green product. (It eventually breaks down into innocuous substances).” </font>
<font>
</font> <font> Market research firm AC Nelson says that the hand sanitizer category is about <font> $100 million market </font> and growing fast, and Purell hand sanitizers have drawn line extension copycat products from Colgate-Palmolive Co., Dial Corp. and Lysol. However, none of these companies can claim to have <font> 99.97% </font> kill rate for Anthrax. This is a market segmentation strategy that major multinationals can not sit around and ignore for much longer since the entire market cap for $BONU is less than <font> $20 million </font> ! </font> <font>
</font> <font> The fact that Ygiene(TM) is a proven hand sanitizer with the ability to kill Anthrax leads me to believe that $BONU ’s patent alone is worth a lot more than the current market cap of roughly <font> $20 million </font> . </font>
<font>
</font> <font> The company’s patented technology is worth far more than <font> $20 million </font> if it can kill Anthrax along with </font> <font> <font> 99.97% </font> </font> <font> of most common germs. There is no doubt that the market for anti-bioterrorism will grow to far over $100 million per year and $BONU ’s Ygiene(TM) could be worth a great deal of money to companies like Pfizer ( $PFE ) and Johnson & Johnson ( $JNJ ) who spend billions of dollars each year developing new innovative products. </font>
$0.0 (07/20/09)
